Illumina (NASDAQ:ILMN) Earns Buy Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Illumina (NASDAQ:ILMN) in a report issued on Sunday. The brokerage issued a buy rating on the life sciences company’s stock.

A number of other research analysts also recently commented on ILMN. OTR Global reiterated a mixed rating on shares of Illumina in a research note on Wednesday, March 20th. Stephens reissued an overweight rating and set a $170.00 target price on shares of Illumina in a report on Tuesday, May 7th. Robert W. Baird increased their target price on shares of Illumina from $125.00 to $128.00 and gave the stock a neutral rating in a report on Friday, May 3rd. Royal Bank of Canada reissued an outperform rating and set a $253.00 target price on shares of Illumina in a report on Tuesday, April 9th. Finally, Jefferies Financial Group assumed coverage on shares of Illumina in a report on Monday, June 3rd. They set a hold rating and a $115.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Illumina presently has an average rating of Hold and an average price target of $157.62.

Illumina Stock Performance

Shares of ILMN stock opened at $105.51 on Friday. Illumina has a one year low of $89.00 and a one year high of $195.64. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.75. The company has a 50 day moving average price of $111.33 and a 200 day moving average price of $127.14. The firm has a market capitalization of $16.81 billion, a price-to-earnings ratio of -12.95 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.05. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. The company had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm earned $0.08 earnings per share. Illumina’s revenue for the quarter was down 1.0% on a year-over-year basis. Sell-side analysts anticipate that Illumina will post 0.98 EPS for the current year.

Institutional Investors Weigh In On Illumina

A number of large investors have recently added to or reduced their stakes in ILMN. Transcend Capital Advisors LLC increased its position in Illumina by 56.0% during the 2nd quarter. Transcend Capital Advisors LLC now owns 5,227 shares of the life sciences company’s stock worth $546,000 after buying an additional 1,877 shares during the period. DekaBank Deutsche Girozentrale grew its holdings in shares of Illumina by 0.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 102,049 shares of the life sciences company’s stock worth $13,969,000 after purchasing an additional 805 shares in the last quarter. Cetera Advisors LLC acquired a new stake in shares of Illumina during the 1st quarter worth $610,000. Cetera Investment Advisers grew its holdings in shares of Illumina by 361.1% during the 1st quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock worth $2,007,000 after purchasing an additional 11,447 shares in the last quarter. Finally, PGGM Investments grew its holdings in shares of Illumina by 7.4% during the 1st quarter. PGGM Investments now owns 227,578 shares of the life sciences company’s stock worth $31,251,000 after purchasing an additional 15,744 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.